241 filings
S-3
LIXT
Lixte Biotechnology Holdings Inc
Shelf registration
23 Apr 24
1:46pm
8-K
LIXT
Lixte Biotechnology Holdings Inc
27 Mar 24
Other Events
7:51pm
8-K
LIXT
Lixte Biotechnology Holdings Inc
22 Mar 24
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
11:17am
10-K
2023 FY
LIXT
Lixte Biotechnology Holdings Inc
Annual report
19 Mar 24
8:30am
8-K
LIXT
Lixte Biotechnology Holdings Inc
27 Feb 24
Professor René Bernards to Present New Pre-Clinical Data
4:59pm
8-K
mtgx0g2bjfmr3cwhzv9
26 Feb 24
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
10:48am
8-K
e0tke
30 Jan 24
Other Events
12:00am
8-K
fecpy5da
28 Nov 23
Departure of Directors or Certain Officers
5:21pm
8-K
un6nrmc 6w75
13 Nov 23
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
2:28pm
8-K
wemu5irv451nlvu0r73
17 Oct 23
Entry into a Material Definitive Agreement
5:27pm
DEFA14A
gf0kv0zm
10 Oct 23
Additional proxy soliciting materials
3:55pm
8-K
scmvxu016tr1sir89e
4 Oct 23
Termination of a Material Definitive Agreement
9:05pm
8-K
vcrye
27 Sep 23
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
6:15am
8-K
fv4q8vvq4ms77sngdub1
20 Sep 23
Other Events
11:20am
EFFECT
5zwv2eo
22 Aug 23
Notice of effectiveness
12:15am
CORRESP
8ubwmuf0
18 Aug 23
Correspondence with SEC
12:00am
UPLOAD
v3dfw0kbi7 wgwd1
15 Aug 23
Letter from SEC
12:00am